Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
| No statute on record | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AMICK, THOMAS RUSSE | 1 | 73.3% | +30.5% |
| CHEN, STACY BROWN | 1 | 65.9% | +40.1% |
| REDDIG, PETER J | 1 | 58.0% | +40.0% |
| DONOGHUE, BRITTNEY ERIN | 1 | 59.8% | +55.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044365 | CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME | REDDIG, PETER J | 99d overdue |
| 18044245 | FUSION PROTEIN COMPRISING CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN AND NUCLEOCAPSID PROTEIN, AND USE THEREOF | CHEN, STACY BROWN | 97d overdue |
| 18559381 | COMPOSITION FOR NK CELL CRYOPRESERVATION AND CRYOPRESERVATION FORMULATION COMPRISING SAME | AMICK, THOMAS RUSSE | 31d overdue |
| 17778168 | COMPOSITION FOR ANTICANCER TREATMENT, COMPRISING NK CELLS AND FUSION PROTEIN WHICH COMPRISES IL-2 PROTEIN AND CD80 PROTEIN | DONOGHUE, BRITTNEY ERIN | 46d |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1672 | 1 |
| 1646 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18559381 | COMPOSITION FOR NK CELL CRYOPRESERVATION AND CRYOPRESERVATION FORMULATION COMPRISING SAME | AMICK, THOMAS RUSSE | 1638 | §102 | Non-Final OA | 31d overdue | Pending | Nov 07, 2023 |
| 18044245 | FUSION PROTEIN COMPRISING CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN AND NUCLEOCAPSID PROTEIN, AND USE THEREOF | CHEN, STACY BROWN | 1672 | Other | Non-Final OA | 97d overdue | Pending | Mar 07, 2023 |
| 18044365 | CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME | REDDIG, PETER J | 1646 | §103 | Non-Final OA | 99d overdue | Pending | Mar 07, 2023 |
| 17778168 | COMPOSITION FOR ANTICANCER TREATMENT, COMPRISING NK CELLS AND FUSION PROTEIN WHICH COMPRISES IL-2 PROTEIN AND CD80 PROTEIN | DONOGHUE, BRITTNEY ERIN | 1675 | Other | Final Rejection | 46d | Pending | May 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial